FI963646A0 - Haarautuneet polyoksa-alkyylimakromolekyylit, menetelmä niiden valmistamiseksi sekä niiden käytöt - Google Patents

Haarautuneet polyoksa-alkyylimakromolekyylit, menetelmä niiden valmistamiseksi sekä niiden käytöt

Info

Publication number
FI963646A0
FI963646A0 FI963646A FI963646A FI963646A0 FI 963646 A0 FI963646 A0 FI 963646A0 FI 963646 A FI963646 A FI 963646A FI 963646 A FI963646 A FI 963646A FI 963646 A0 FI963646 A0 FI 963646A0
Authority
FI
Finland
Prior art keywords
branched
polyoxa
macromolecules
alkyl
preparation
Prior art date
Application number
FI963646A
Other languages
English (en)
Swedish (sv)
Other versions
FI963646A (fi
Inventor
Luigia Gozzini
Monica Muttoni
Haen Christoph De
Original Assignee
Bracco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Spa filed Critical Bracco Spa
Publication of FI963646A0 publication Critical patent/FI963646A0/fi
Publication of FI963646A publication Critical patent/FI963646A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polyesters Or Polycarbonates (AREA)
FI963646A 1994-03-18 1996-09-16 Haarautuneet polyoksa-alkyylimakromolekyylit, menetelmä niiden valmistamiseksi sekä niiden käytöt FI963646A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI940512A IT1270994B (it) 1994-03-18 1994-03-18 Macromolecole ramificate a struttura poliossialchilica e loro usi
PCT/EP1995/000943 WO1995025763A1 (en) 1994-03-18 1995-03-14 Branched polyoxaalkyl macromolecules, process for making them and their uses

Publications (2)

Publication Number Publication Date
FI963646A0 true FI963646A0 (fi) 1996-09-16
FI963646A FI963646A (fi) 1996-09-16

Family

ID=11368259

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963646A FI963646A (fi) 1994-03-18 1996-09-16 Haarautuneet polyoksa-alkyylimakromolekyylit, menetelmä niiden valmistamiseksi sekä niiden käytöt

Country Status (14)

Country Link
US (1) US5780644A (fi)
EP (1) EP0750649B1 (fi)
JP (1) JPH09510489A (fi)
KR (1) KR970701748A (fi)
AT (1) ATE211155T1 (fi)
AU (1) AU689244B2 (fi)
CA (1) CA2185647A1 (fi)
DE (1) DE69524738T2 (fi)
FI (1) FI963646A (fi)
IL (1) IL113004A (fi)
IT (1) IT1270994B (fi)
NO (1) NO312901B1 (fi)
WO (1) WO1995025763A1 (fi)
ZA (1) ZA952165B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019240A1 (en) * 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates
IT1277414B1 (it) * 1995-08-02 1997-11-10 Bracco Spa Uso di macromolecole di tipo dendrimerico come catalizzatori o coadiuvanti delle reazioni in condizioni di trasferimento di fase
IT1277596B1 (it) * 1995-09-15 1997-11-11 Bracco Spa Composti macromolecolari di tipo dendrimerico
AU730969B2 (en) * 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
DE19624705A1 (de) * 1996-06-20 1998-01-08 Deutsches Krebsforsch Dendrimere auf Saccharid-Basis
US6214988B1 (en) 1999-01-03 2001-04-10 Schlumberger Technology Corporation Process for making an HMX product
US6428724B1 (en) 1999-05-26 2002-08-06 Schlumberger Technology Corporation Granulation process
US6201117B1 (en) 1999-05-26 2001-03-13 Schlumberger Technology Corporation Process for making a 1,3,5,7-tetraalkanoyl-1,3,5,7-tetraazacyclooctane
US6194571B1 (en) 1999-05-26 2001-02-27 Schlumberger Technology Corporation HMX compositions and processes for their preparation
US6265573B1 (en) 1999-05-26 2001-07-24 Schlumberger Technology Corporation Purification process
AU6386000A (en) 1999-07-29 2001-02-19 Epix Pharmaceuticals, Inc. Targeting multimeric imaging agents through multilocus binding
US7560520B1 (en) 2004-11-08 2009-07-14 The United States Of America As Represented By The Secretary Of The Army Interface-directed branched polymer transports and methods for producing same
US7645854B2 (en) * 2005-03-04 2010-01-12 Central Michigan University Board Of Trustees Conjugate addition products of primary amines and activated acceptors
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2679711C (en) 2007-03-15 2018-05-01 Huntsman Petrochemical Corporation High functionality amine compounds and uses therefor
EP2552998A4 (en) * 2010-03-30 2013-11-06 Spago Imaging Ab COMPACT, BRANCHED POLYETHYLENE GLYCOL DERIVATIVES
US8816099B2 (en) 2010-03-31 2014-08-26 Nof Corporation Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof
US9133114B2 (en) * 2012-01-31 2015-09-15 University Of Maryland, Baltimore Dendrimers and methods of preparing same through proportionate branching

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4737550A (en) * 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US5099042A (en) * 1989-03-14 1992-03-24 Thiokol Corporation Synthesis of tetrafunctional polyethers and compositions formed therefrom
US5041516A (en) * 1989-06-21 1991-08-20 Cornell Research Foundation, Inc. Dendritic molecules and method of production
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants

Also Published As

Publication number Publication date
IL113004A0 (en) 1995-06-29
NO312901B1 (no) 2002-07-15
WO1995025763A1 (en) 1995-09-28
DE69524738D1 (de) 2002-01-31
IT1270994B (it) 1997-05-26
NO963872L (no) 1996-09-16
ITMI940512A0 (it) 1994-03-18
ATE211155T1 (de) 2002-01-15
ITMI940512A1 (it) 1995-09-18
JPH09510489A (ja) 1997-10-21
AU689244B2 (en) 1998-03-26
AU2070395A (en) 1995-10-09
US5780644A (en) 1998-07-14
CA2185647A1 (en) 1995-09-28
NO963872D0 (no) 1996-09-16
KR970701748A (ko) 1997-04-12
EP0750649A1 (en) 1997-01-02
DE69524738T2 (de) 2002-06-13
IL113004A (en) 2000-08-31
FI963646A (fi) 1996-09-16
ZA952165B (en) 1995-12-14
EP0750649B1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
FI963646A (fi) Haarautuneet polyoksa-alkyylimakromolekyylit, menetelmä niiden valmistamiseksi sekä niiden käytöt
FI963283A (fi) 4-asemasta heterosyklyylillä substituoituja kinatsoliinijohdannaisia, menetelmiä niiden valmistamiseksi ja niiden käyttö syöpälääkkeinä
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
HN1996000017A (es) Isotiazolonas
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
ATE279942T1 (de) Mehrwertige impstoffzusammensetzung mit gemischten trägern
NO20002786D0 (no) Adamantanderivater
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
NL1000241C2 (nl) Transportband.
DK1051158T3 (da) Farmaceutiske præparater i form af polymere mikropartikler fremstillet ved ekstrudering og sfæronisering
FI954475A (fi) Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi
DE59703693D1 (de) Pflanzenbehandlungsmittel
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
TR200201251T2 (tr) Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri
FI955777A (fi) Menetelmä ja tuotteisto hiusten käsittelyn suorittamiseksi
TR199900285A2 (xx) Yeni eritromisin t�revleri ve bunlar� i�eren ila�lar.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
DE69000648D1 (de) Selbsttragendes, transportables und raeumlich ausfahrbares erzeugnis.
NL1002261C2 (nl) Postduivenring.
ES2150698T3 (es) Derivados de fenilacetamida.
FI956045A (fi) Antiparasiittisina aineina käyttökelpoiset 14-substituoidut markfortiinit ja johdannaiset
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES1030395U4 (es) Banda transportadora perfeccionada.
SE9500863D0 (sv) Låsanordning för smycken, exempelvis örhängen

Legal Events

Date Code Title Description
MA Patent expired